Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)
Dizal Pharmaceuticals
James Chih-Hsin Yang; Mengzhao Wang; Ludovic Doucet; Yun Fan; Dongqing Lv; Meili Sun; Dingzhi Huang; Laurent Greillier; David Planchard; Qunying Hong; Julien Mazieres; Enriqueta Felip; Xingya Li; Ying Hu; Jian Fang; Lyudmila Bazhenova; François Ghiringhelli; Manuel Angel Cobo Dols; Luis Paz-Ares Rodriguez; Alessandra Bearz; Bruna Pellini; Yu Jung Kim; Joaquim Bosch-Barrera; Byoung-Yong Shim; Yung-Hung Luo; Marcello Tiseo; Tsung-Ying Yang; Enric Carcereny; Regan M Memmott; Gerard Zalcman; Javier de Castro Carpeno; Vincenzo Di Noia; Hector Soto Parra; Guillermo Streich; Dae Ho Lee; Elaine Shum; Ji-Youn Han; Jesus Corral Jaime; Daniel Brungs; Thomas John; Manolo D'Arcangelo; Andres Barba Joaquin; Geoffrey Liu; Lorenzo Antonuzzo; Gonzalo Fernández Hinojal; Xiuning Le; Li Zheng; Pasi A Jänne; WU-KONG1B